Field of the Invention
The disclosed embodiments relate to compositions, devices, and methods related to promoting blood clotting.
Description of the Related Art
Blood is a liquid tissue that includes red cells, white cells, corpuscles, and platelets dispersed in a liquid phase. The liquid phase is plasma, which includes acids, lipids, solubilized electrolytes, and proteins. The proteins are suspended in the liquid phase and can be separated out of the liquid phase by any of a variety of methods such as filtration, centrifugation, electrophoresis, and immunochemical techniques. One particular protein suspended in the liquid phase is fibrinogen. When bleeding occurs, the fibrinogen reacts with water and thrombin (an enzyme) to form fibrin, which is insoluble in blood and polymerizes to form clots.
In a wide variety of circumstances, wounds can be inflicted as the result of trauma. Often bleeding is associated with such wounds. In some circumstances, the wound and the bleeding are minor, and normal blood clotting functions in addition to the application of simple first aid are all that is required. First aid may include applying pressure to the wound with a sponge or similar device to facilitate clotting functions. Unfortunately, however, in other circumstances substantial bleeding can occur. Bleeding can also be a problem when the trauma is the result of a surgical procedure. Apart from suturing or stapling an incision or internally bleeding area, bleeding encountered during surgery is often controlled using sponges or other materials used to exert pressure against the bleed site and/or absorb the blood. However, in many circumstances these measures are not sufficient, such as when the bleeding becomes excessive, or when the wound is difficult to reach, or when it is advantageous to be able to view continuously the wound area.
Compositions comprising a clay, or a component of a clay, dispersed in a liquid medium can be useful as hemostatic or blood-clotting compositions or agents. These compositions may be useful for promoting the clotting of blood for animals or human beings, including clotting blood in individuals with a compromised ability to clot blood, such as individuals taking anticoagulant drugs such as heparin, warfarin, clopidogrel, coumarin, etc., or individuals suffering from clotting disorders such as Hemophilia A, Hemophilia B, von Willebrand disease, etc.
Some embodiments include a blood-clotting agent comprising: a composition comprising clay dispersed in a liquid medium, wherein the clay is less than about 10% by weight of the composition; and wherein the composition including the liquid medium and clay has a viscosity of about 1000 cP or less.
Some embodiments include a blood-clotting agent comprising: a composition comprising clay dispersed in a liquid medium, wherein the clay is less than about 10% by weight of the composition; and wherein the composition including the liquid medium and clay has a viscosity of about 1000 cP to about 100,000 cP.
Some embodiments include a hemostatic composition comprising: a clay dispersed in an aqueous medium; wherein the composition is a liquid which is substantially free of visible clay particles; and wherein the composition is sterilized.
Some embodiments comprise a hemostatic composition comprising: kaolin dispersed in an aqueous medium; wherein the composition is flowable; wherein at least 50% of the kaolin has a particle size in the range of about 1 nm to about 1000 nm; and wherein the composition is sterilized.
Some embodiments include a hemostatic device comprising: a vessel which contains a hemostatic composition of the type described herein; and a dispensing component in fluid communication with the vessel; wherein the device is configured so that the dispensing component is capable of dispensing the hemostatic composition from the vessel to a bleeding area of an animal or person.
Some embodiments comprise a hemostatic composition comprising: a liquid comprising a first component of a kaolin, wherein the first component of the kaolin is prepared by a process comprising: dispersing the kaolin in an aqueous medium; and separating the first component of the kaolin from a second component of the kaolin; wherein the first component of the kaolin has an average particle size which is smaller than an average particle size of the second component of kaolin.
Some embodiments include a hemostatic composition comprising: a component of kaolin dispersed in an aqueous medium; wherein the component of kaolin is capable of remaining dispersed in the aqueous medium for at least about 60 minutes without agitation.
Some embodiments include a hemostatic composition comprising: a component of kaolin dispersed in an aqueous medium; wherein the component of kaolin is capable of remaining dispersed in the aqueous medium for at least about 5 minutes in a centrifuge at a centripetal acceleration of at least about 1000 m/s2.
Some embodiments include a blood-clotting composition comprising: a fine kaolin having a reduced particle size as compared to a particle size of a naturally and/or commonly occurring kaolin; and water; wherein the fine kaolin is dispersed in the water to form a stable kaolin-water dispersion.
Some embodiments include a hemostatic system comprising: a hemostatic device comprising: a vessel comprising an interior volume configured to contain a liquid; an orifice in fluid communication with the interior volume comprising a rim surrounding the orifice, wherein the rim is configured to form a seal, a removable adhesive connection, or a contact surface with a part of an animal body or a human body; a fluid input component configured to provide a liquid to the interior volume of the vessel; and a fluid output component configured to allow liquid to exit the interior volume of the vessel; and a composition of the type described herein.
As used herein, the term “hemostatic composition” is used in accordance with the ordinary meaning in the art and includes a blood-clotting agent, a blood-clotting composition, a hemostatic composition, a hemostatic agent, or a similar material. A hemostatic composition may comprise a clay or a component of a clay which may be dispersed in a liquid medium.
A liquid medium may include any liquid, including an aqueous liquid. In some embodiments, the liquid medium may contain at least: about 10%, about 50%, or about 90% water by weight. Other liquids, including organic liquids, may be used. For example, alcohols such as glycerin, ethanol, methanol, isopropanol, and the like, may also be used. A combination of non-aqueous liquids or a combination of water and other liquids may also be used. In some embodiments, tap water, saline water, distilled water, or sterile water may be used.
A clay may include any clay such as kaolin, bentonite, montmorillonite, saponite, polygorskite or attapulgite, sepiolite, etc. In some embodiments, the clay may be a kaolin clay, which may include the mineral “kaolinite.” The kaolin may include Edgar's plastic kaolin (hereinafter “EPK”), which is a water-washed kaolin clay that is mined and processed around Edgar, Fla.
A hemostatic composition may be prepared by adding an appropriate amount of clay to a liquid. This mixture may be used with these constituents by themselves and/or without further treatment or processing (besides possibly sterilization). In some embodiments, the mixture may be subjected to a separation process which may produce a separation of the clay into components or may provide clay particles in particular ranges of sizes. Thus, in some embodiments, one or more components or particular size ranges of clay may be used in addition to or in place of a native or standard type of clay. The component or particular size range of clay may be obtained by a separation process or may be separately obtained and added to a liquid. As used herein, unless otherwise indicated, the term “clay” should be understood to include clay, a component of clay, or a combination thereof.
In some embodiments, a first component of a clay may be separated from a second component of a clay. One or more separation processes may further provide additional components of the clay, such as a third component, a fourth component, etc. An example of a method that may be used to accomplish a separation may be dispersing a clay in a liquid, and then separating the dispersion by filtration or using one or more settling methods such as centrifugation or standing.
A separation may produce a first component which is distinct from other components in some way. Some separations involve separating a fraction which has more liquid from a fraction which has more solid, as compared to the composition before the separation is carried out. A liquid fraction may include a supernatant, or the liquid portion removed from the top of a centrifuged mixture, or a filtrate, or the liquid which is passed through a filter during a filtration. A solid fraction may include the sediment or solid material from a centrifugation or the filtered solid material obtained by filtration. In some embodiments, a first component of a clay is separated from a second component of a clay by centrifuge or filtration.
In some embodiments, a first component may consist essentially of or include higher levels of ions of calcium (e.g. Ca+, Ca2+, etc.), aluminum (e.g. Al+, Al2+, Al3+, etc.), iron (e.g. Fe+, Fe2+, Fe3+, etc.) magnesium (e.g. Mg+, Mg2+, etc.), potassium (e.g. K+), sodium (e.g. Na+), or other ions. If the first component comprises a liquid fraction, this may be because the ions are soluble in the liquid, and thus retained with the liquid fraction. For example, the molar ratio of one or more of these ions in a first component as compared to a second component may be at least about 1.1, about 2, or about 5 to about 10, about 100, or about 1000. Ions such as those listed above may also be added directly to the composition.
In some embodiments, a first component may have an average particle size which is smaller than the average particle size of a second component or another component of the clay.
While a clay may be present in any amount, a clay may be at least: about 0.00001%, about 0.001%, or about 0.01% by weight of the composition, and/or may further be about 10% or less, about 5% or less, or about 1% or less by weight of the composition. In some embodiments, a hemostatic composition may include clay particles of a size that renders the composition substantially free of visible clay particles to an observer with an unaided eye. In some embodiments, the turbidity of the composition may be at least: about 0.001 Nephelometric Turbitidy Units (NTU), about 0.01 NTU, or about 0.3 NTU, and/or may further be about 5 or less, about 50 or less, or about 200 or less. In some embodiments, the clay may be dispersed in a liquid to provide a stable clay-liquid dispersion, such as a stable clay-water dispersion or kaolin-water dispersion. In some embodiments, an appreciable amount of the clay particles may not settle from an aqueous liquid upon standing. In some embodiments, the clay particles may not settle from an aqueous liquid upon standing for at least about 5 minutes, at least about 1 hour, at least about 12 hours, at least about 1 day, at least about 1 month, or at least about 1 year. In some embodiments, the clay particles may be capable of remaining dispersed in an aqueous liquid for at least about 1 minute, at least about 5 minutes, at least about 30 minutes, or at least about an hour in a centrifuge at a centripetal acceleration of at least about 100 m/s, at least about 1000 m/s, or at least about 10,000 m/s.
A clay may have a particle size in a range that allows it to be dispersed in the liquid. For example, in some embodiments, at least about 50%, at least about 90%, or at least about 95% of a clay, such as kaolin, may have a particle size in the range of about 1 nm to about 10 μm, about 10 nm to about 5 μm, or about 50 nm to about 5 μm. In some embodiments, a fine clay may be used which has a reduced particle size as compared to a particle size of a naturally and/or commonly occurring clay. In some embodiments, the fine clay may be fine kaolin.
Tonicity agents may be included or omitted in a hemostatic composition to adjust tonicity, for example, to make the composition isotonic, hypertonic, or hypotonic. Tonicity may be adjusted by adjusting the concentration of a tonicity agent. For example, reducing the concentration of a tonicity agent may reduce the tonicity of the composition, and increasing the concentration of a tonicity agent may increase the tonicity of the composition. Suitable tonicity agents include, but are not limited to, sugars, such as glucose and isomers thereof, dextrose, fructose and isomers thereof, disaccharides, etc.; alkali salts (e.g. Group I salts), such as salts of Na+, K+, etc.; halide salts, such as salts of Cl−, Br−, I−, etc.; polyols such as glycerin and other sugar alcohols such as mannitol, sorbitol, etc.; etc.
A hemostatic composition may be sterile or sterilized. An antimicrobial agent may be included in some embodiments, which may help to preserve the sterility of a composition over time, or may help to improve or preserve the sterility of the bleeding area while a hemostatic composition is used to promote clotting of a wound. Suitable antimicrobial agents may include, but are not limited to, compounds or salts containing silver ions; compounds or salts containing copper ions; and halogen-based antimocrobials such as iodine, bromine, and chlorine, and salts or oxides thereof, such as ClO−, BrO−, IO−, etc. In some embodiments, the antimicrobial agent may comprise a stabilized halogen or halogen containing salt. One example of an antimicrobial agent includes povidone (also known as polyvinylpyrrolidone) and/or iodine, such as a 10% povidone iodine solution.
A hemostatic composition may comprise a therapeutically active agent. Examples of therapeutically active agents may include, but are not limited to, analgesics, including but not limited to, opiates such as codeine, morphine, oxycodone, etc.; acetaminophen; anti-inflammatory agents, including nonsteroidal anti-inflammatory drugs, aspirin, etc.; antibiotics or another antimicrobial drugs or compounds; antihistamines (e.g., cimetidine, chloropheniramine maleate, diphenhydramine hydrochloride, and promethazine hydrochloride); antifungal agents; ascorbic acid; tranexamic acid; rutin; thrombin; botanical agents; etc.; and combinations thereof. Other additives may include magnesium sulfate, sodium metaphosphate, calcium chloride, dextrin, and combinations thereof.
A hemostatic agent may be in any form, such as a liquid, a gel, a paste, a foam, a cream, a particle, a powder, or other form. In some embodiments, a hemostatic composition may be flowable. For example, a hemostatic composition may have a viscosity from at least: about 0.1 cP, about 0.2 cP, about 0.5 cP, about 1 cP; and/or less than or equal to: about 1000 cP, about 10,000 cP, or about 100,000 cP. The viscosity may vary according to the type of injury or situation in which the composition is used and/or the form of the composition. For example, in some embodiments, a liquid with a viscosity similar to water, such as a viscosity at or below about 1000 cP, about 100 cP, or about 10 cP, may be desired for surgical applications. In some situations, such as in treating a wound formed by a bullet or another type of penetrating wound, a form of composition that is thicker or more viscous than water may be used, such as a gel or foam, to allow the composition to generally plug up or generally fill or generally obstruct or generally impede communication between the internal injured area and the area outside of the body to diminish the egress of blood from the wound and the ingress of contaminants into the wound. The composition may, in some instances, have much higher viscosities, such as at least: about 1000 cP, about 10,000 cP, or about 50,000 cP; and/or less than or equal to: about 100,000 cP, about 150,000 cP, or about 250,000 cP.
For some forms of thicker or more viscous compositions, such as gels, pastes, foams, or other forms, a thickening agent, such as a gelling agent, may be added to increase the viscosity of the liquid. The thickening agent may also help to keep a hemostatic agent such as a clay from settling from the dispersion. Any thickening agent may be used, including, but not limited to, cellulose derivatives such as carboxymethylcellulose, hydroxypropylmethylcellulose, methylcellulose, hydroxypropylcellulose, etc.; other carbohydrates or polysaccharides, or derivatives thereof, such as dextrans, starches, starch derivatives, carrageenan, guar gum, gum karaya, xanthan gum, gum arabic, gum tragacanth, etc.; polycarboxylic acids such as polyacrylic acid, polymethacrylic acid, etc.; fatty acids such as myristic acid, palmitic acid, stearic acid, arachidic acid, and behenic acid, palmitoleic acid, oleic acid, linoleic acid, α-linolenic acid, γ-linolenic acid, arachidonic acid, eicosapentaenoic acid, etc.; polyalkylene glycol polymers or copolymers such as polyethylene glycol, polyethylene glycol-polypropylene glycol copolymers, etc.
A hemostatic composition may also contain cations such as calcium (e.g. Ca+, Ca2+, etc.), aluminum (e.g. Al+, Al2+, Al3+, etc.), iron (e.g. Fe+, Fe2+, Fe3+, etc.) magnesium (e.g. Mg+, Mg2+, etc.), potassium (e.g. K+), sodium (e.g. Na+), silver, etc.
A hemostatic composition may be applied to any bleeding area of an animal or human being. Examples of injuries which may involve bleeding which could be treated with a hemostatic composition include, but are not limited to, injuries related to surgery, injuries caused by a weapon such as a bullet, a blade such as a knife, sword or bayonet, an explosive weapon, etc.
In some situations, such as in treating an injury characterized by a generally long, generally tube-shaped bleeding hole (e.g., a bullet track or an injury caused by a biopsy), treatment may be accomplished by applying slightly more pressure to the infused hemostatic liquid than that of the exiting blood to position the hemostatic material at a suitable location within or proximate to the injury to assist in diminishing or halting bleeding. For example, the pressure may be at least: about 180 mmHg, about 200 mmHg, about 250, about 300 mmHg; and/or less than or equal to: about 500 mmHg, about 700 mmHg, or about 1000 mmHg. In some embodiments, the pressure may be about 300 mmHg.
The term “vessel” is used herein in accordance with its ordinary meaning in the art and includes any structure which is capable of holding a hemostatic composition and being in fluid communication with a dispensing component. Examples may include, but are not limited to, containers such as bottles, vials, canisters, tubes, reservoirs, etc., and materials which may hold the composition such as a sponge, a cloth, a gauze, etc. A dispensing component may be any feature which is capable of being in fluid communication with a vessel and dispensing a hemostatic composition from the vessel to a bleeding area of an animal or person. Examples may include, but are not limited to, valves, lumens, orifices, pumps, sponges, cloths, etc. In some embodiments, a hemostatic device may comprise an absorbent material, such as a sponge, cloth, gauze, etc., wherein a liquid hemostatic composition is absorbed therein. The absorbent material may be saturated, meaning that the material cannot absorb any more liquid, or it may contain a liquid hemostatic composition but not be saturated. These devices may be further packaged in a film or other sealing material to reduce evaporation or other loss of the liquid.
A hemostatic composition may be dispensed by and/or incorporated into a hemostatic device.
As shown in
A hemostatic composition may be incorporated into other systems or methods in many different types of various applications, such as surgery. These methods or systems may comprise a hemostatic composition in liquid form (or a “hemostatic liquid”) and a liquid provision component configured to provide the hemostatic liquid to an area of a human being or animal affected by a surgical procedure, such as an area that is bleeding as a result of a surgical procedure. The liquid provision component may be any structure, component, or device which is capable of providing the hemostatic liquid to the area affected by a surgical procedure (e.g., through irrigation). For example, the hemostatic liquid may be provided during surgery, while surgery is being completed, after surgery is completed, etc. Examples may include, but are not limited to, surgical tubing with a hand piece comprising a valved dispensing portion to permit selective dispensing or irrigation. A system or method may further comprise a liquid-removal component configured to remove liquids, such as the hemostatic liquid, blood, or other liquids, from the area of the human being or animal affected by the surgical procedure (e.g., through aspiration). The liquid-removal component may be any structure, component, or device which is capable of removing liquid from the area affected by a surgical procedure. Examples may include, but are not limited to, tubing, such as surgical tubing. The liquid removal component may further be configured to remove the hemostatic liquid while the surgery is taking place, as surgery is being completed, after surgery is completed, etc. The liquid-delivery and liquid-removal components can be included together on a single hand piece or can be provided separately. An actuator positioned on the hand piece or surgical tubing can activate either or both of the irrigation and aspiration features, or toggle between them.
In some embodiments, a hemostatic system may comprise a hemostatic device that may comprise a vessel and a hemostatic composition. The vessel may be any vessel which is configured to contain a liquid. This vessel may further comprise an interior volume configured to contain a liquid, and an orifice in fluid communication with the interior volume comprising a rim surrounding the orifice, wherein the rim is configured to generally provide contact with or to generally form a seal with a part of an animal body or a human body.
A rim may be a rim similar to a rim of a cup or a glass, or it may simply be formed by a hole on an external surface of the vessel. It may be even with an external surface of the vessel or may be raised with respect to the surface of the vessel. In some embodiments, the rim may be flexible or resilient. A seal may be formed by causing the rim to be pressed against the body part and/or by disposing an adhesive material on the rim so that a seal is formed by temporary adhesion between the rim and the body part.
A vessel may further comprise a fluid input component configured to provide a liquid to an interior volume of the vessel. The fluid input component may be any structural feature or combination of features which may provide a liquid to an interior volume of a vessel, such as an orifice or a valve.
A vessel may further comprise a fluid output component configured to allow liquid to exit from the vessel. The fluid output component may be any structural feature or combination of features which may allow liquid to exit from the vessel, such as an orifice or a valve.
Kaolin (about 0.34 g) and glycerin (about 0.91 g) are mixed with sterile, distilled, non pyrogenic, pH 7.0 water (about 42 mL). The mixture appears cloudy or turbid.
The mixture of Example 1 is centrifuged for about 5 minutes at about 3000 rpm. The supernatant is carefully collected and the precipitate is discarded to yield a liquid hemostatic composition which appears substantially clearer.
The composition of Example 2 (about 3 mL) is combined with 10% povidone iodine (about 3 mL).
The composition of Example 2 (about 6 mL) is combined with 10% povidone iodine (about 3 mL).
The compositions prepared as described in Examples 1-3, and water were tested for clotting. The test was carried out by combining 0.5 ml of the hemostatic composition with 1 ml of citrated sheep blood and 150 μL of CaCl2 in a test tube.
The clotting times for the four samples are shown in Table 1 below.
Although the embodiments have been described in the context of certain examples, it will be understood by those skilled in the art that the scope of the claims may extend beyond the specifically disclosed embodiments to other embodiments including embodiments formed of combinations of features disclosed herein and equivalents thereof.
The present application is a continuation of U.S. patent application Ser. No. 15/641,999, filed Jul. 5, 2017, now pending, which is a continuation of U.S. patent application Ser. No. 14/995,592, filed Jan. 14, 2016, now U.S. Pat. No. 9,889,154, which is a continuation of U.S. patent application Ser. No. 14/479,214, filed Sep. 5, 2014, abandoned, which is a continuation of U.S. patent application Ser. No. 13/240,795, filed Sep. 22, 2011, now U.S. Pat. No. 8,858,969, which claims the priority benefit of U.S. Patent Application No. 61/385,388, filed Sep. 22, 2010. These applications and any other applications for which a foreign or domestic priority claim is identified in the Application Data Sheet filed with the present application are hereby incorporated by reference for all purposes in their entireties herein under 37 C.F.R. § 1.57.
Number | Name | Date | Kind |
---|---|---|---|
2688586 | Eberl et al. | Sep 1954 | A |
2922719 | Robinson | Jan 1960 | A |
2969145 | Hannuer, Jr. | Jan 1961 | A |
3122140 | Crowe et al. | Feb 1964 | A |
3181231 | Breck | May 1965 | A |
3189227 | Hobbs et al. | Jun 1965 | A |
3366578 | Michalko | Jan 1968 | A |
3386802 | Michalko | Jun 1968 | A |
3538508 | Young | Nov 1970 | A |
3550593 | Kaufman | Dec 1970 | A |
3608070 | Nouvel | Sep 1971 | A |
3658984 | Kamp | Apr 1972 | A |
3698392 | Vogt et al. | Oct 1972 | A |
3723352 | Warner et al. | Mar 1973 | A |
3763900 | Solms-Baruth et al. | Oct 1973 | A |
3979335 | Golovko et al. | Sep 1976 | A |
4373519 | Errede et al. | Feb 1983 | A |
4374044 | Schaefer et al. | Feb 1983 | A |
4379143 | Sherry et al. | Apr 1983 | A |
4435512 | Ito et al. | Mar 1984 | A |
4460642 | Errede et al. | Jul 1984 | A |
4514510 | Alexander | Apr 1985 | A |
4524064 | Nambu | Jun 1985 | A |
4525410 | Hagiwara et al. | Jun 1985 | A |
4569343 | Kimura et al. | Feb 1986 | A |
4626550 | Hertzenberg | Dec 1986 | A |
4631845 | Samuel et al. | Dec 1986 | A |
4651725 | Kifune et al. | Mar 1987 | A |
4717735 | Stem | Jan 1988 | A |
4728323 | Matson | Mar 1988 | A |
4748978 | Kamp | Jun 1988 | A |
4822349 | Hursey et al. | Apr 1989 | A |
4828081 | Nordstrom et al. | May 1989 | A |
4828832 | DeCuellar et al. | May 1989 | A |
4911898 | Hagiwara et al. | Mar 1990 | A |
4938958 | Niira et al. | Jul 1990 | A |
4956350 | Mosbey | Sep 1990 | A |
5140949 | Chu et al. | Aug 1992 | A |
5144016 | Skjak-Braek et al. | Sep 1992 | A |
5146932 | McCabe | Sep 1992 | A |
5474545 | Chikazawa | Dec 1995 | A |
5482932 | Thompson | Jan 1996 | A |
5486195 | Myers et al. | Jan 1996 | A |
5502042 | Gruskin et al. | Mar 1996 | A |
5538500 | Peterson | Jul 1996 | A |
5556699 | Niira et al. | Sep 1996 | A |
5575995 | Giovanoni | Nov 1996 | A |
5578022 | Scherson et al. | Nov 1996 | A |
5597581 | Kaessmann et al. | Jan 1997 | A |
5599578 | Butland | Feb 1997 | A |
D386002 | Hinkle | Nov 1997 | S |
5696101 | Wu et al. | Dec 1997 | A |
5716337 | McCabe et al. | Feb 1998 | A |
5725551 | Myers et al. | Mar 1998 | A |
5728451 | Langley et al. | Mar 1998 | A |
5766715 | Garconnet | Jun 1998 | A |
5788682 | Maget | Aug 1998 | A |
5801116 | Cottrell et al. | Sep 1998 | A |
5826543 | Raymond et al. | Oct 1998 | A |
5855570 | Scherson et al. | Jan 1999 | A |
5891074 | Cerarczyk | Apr 1999 | A |
5916511 | Kotani et al. | Jun 1999 | A |
5941897 | Myers | Aug 1999 | A |
5964239 | Loux et al. | Oct 1999 | A |
5964349 | Odagiri | Oct 1999 | A |
5981052 | Siguyama | Nov 1999 | A |
5993964 | Nakajima | Nov 1999 | A |
6037280 | Edwards et al. | Mar 2000 | A |
6060461 | Drake | May 2000 | A |
6086970 | Ren | Jul 2000 | A |
6123925 | Barry et al. | Sep 2000 | A |
6159232 | Nowakowski | Dec 2000 | A |
6187347 | Patterson et al. | Feb 2001 | B1 |
6203512 | Farris et al. | Mar 2001 | B1 |
6251423 | Brandford | Jun 2001 | B1 |
6372333 | Sugiyama et al. | Apr 2002 | B1 |
6428800 | Greenspan et al. | Aug 2002 | B2 |
6450537 | Norris | Sep 2002 | B2 |
6475470 | Kayane et al. | Nov 2002 | B1 |
6481134 | Aledo | Nov 2002 | B1 |
6486285 | Fujita | Nov 2002 | B2 |
6495367 | Isogawa et al. | Dec 2002 | B1 |
6523778 | Key et al. | Feb 2003 | B2 |
6573419 | Naimer | Jun 2003 | B2 |
6590337 | Nishikawa et al. | Jul 2003 | B1 |
6622856 | Gallo et al. | Sep 2003 | B2 |
6630140 | Grunstein | Oct 2003 | B1 |
6638073 | Kazimirov et al. | Oct 2003 | B1 |
6685227 | Merry et al. | Feb 2004 | B2 |
6700032 | Gray | Mar 2004 | B1 |
6701649 | Brosi | Mar 2004 | B1 |
6745720 | Rasner et al. | Jun 2004 | B2 |
6805961 | Watanabe et al. | Oct 2004 | B1 |
6890177 | Dragan | May 2005 | B2 |
6998510 | Buckman et al. | Feb 2006 | B2 |
7125821 | Xu et al. | Oct 2006 | B2 |
7303759 | Mershon | Dec 2007 | B2 |
7322976 | Yassinzadeh | Jan 2008 | B2 |
7371403 | McCarthy et al. | May 2008 | B2 |
7429252 | Sarangapani | Sep 2008 | B2 |
7572274 | Yassinzadeh | Aug 2009 | B2 |
7595429 | Hursey | Sep 2009 | B2 |
7604819 | Huey et al. | Oct 2009 | B2 |
7691127 | Yassinzadeh | Apr 2010 | B2 |
7815640 | Yassinzadeh | Oct 2010 | B2 |
7825133 | Yi | Nov 2010 | B2 |
7858123 | Stucky | Dec 2010 | B2 |
7968114 | Huey et al. | Jun 2011 | B2 |
7993366 | Yassinzadeh et al. | Aug 2011 | B2 |
8063264 | Spearman et al. | Nov 2011 | B2 |
8114433 | Huey et al. | Feb 2012 | B2 |
8118777 | Ducharme et al. | Feb 2012 | B2 |
8202532 | Huey et al. | Jun 2012 | B2 |
8252318 | Huey et al. | Aug 2012 | B2 |
8252344 | Hursey | Aug 2012 | B2 |
8257731 | Horn et al. | Sep 2012 | B2 |
8257732 | Huey et al. | Sep 2012 | B2 |
8277837 | Fischer et al. | Oct 2012 | B2 |
8323305 | Epstein et al. | Dec 2012 | B2 |
8343537 | Huey et al. | Jan 2013 | B2 |
8361054 | Ducharme et al. | Jan 2013 | B2 |
8383148 | Huey et al. | Feb 2013 | B2 |
8439944 | Yassinzadeh | May 2013 | B2 |
8444671 | Yassinzadeh | May 2013 | B2 |
8460699 | Huey et al. | Jun 2013 | B2 |
8497408 | Whek et al. | Jul 2013 | B2 |
8512743 | Horn et al. | Aug 2013 | B2 |
8535709 | Kennedy et al. | Sep 2013 | B2 |
8557278 | Huey et al. | Oct 2013 | B2 |
8595429 | Gu et al. | Nov 2013 | B2 |
8703634 | Baker et al. | Apr 2014 | B2 |
8747435 | Yassinzadeh | Jun 2014 | B2 |
8784876 | Huey et al. | Jul 2014 | B2 |
8846076 | Huey et al. | Sep 2014 | B2 |
8858969 | Pahari et al. | Oct 2014 | B2 |
8911472 | Yassinzadeh et al. | Dec 2014 | B2 |
8938898 | Lo et al. | Jan 2015 | B2 |
9017374 | Yassinzadeh | Apr 2015 | B2 |
9072806 | Lo et al. | Jul 2015 | B2 |
9078782 | Huey et al. | Jul 2015 | B2 |
9179897 | Yassinzadeh et al. | Nov 2015 | B2 |
9333117 | Huey et al. | May 2016 | B2 |
9352066 | Dubey | May 2016 | B2 |
9370347 | Yassinzadeh | Jun 2016 | B2 |
9427221 | Yassinzadeh | Aug 2016 | B2 |
9439637 | Yassinzadeh et al. | Sep 2016 | B2 |
9597066 | Yassinzadeh et al. | Mar 2017 | B2 |
9603964 | Dubey et al. | Mar 2017 | B2 |
9839772 | Ducharme | Dec 2017 | B2 |
9867898 | Huey et al. | Jan 2018 | B2 |
9867931 | Gittard | Jan 2018 | B2 |
9889154 | Basadonna et al. | Feb 2018 | B2 |
10130347 | Yassinzadeh | Nov 2018 | B2 |
20020077653 | Hudson et al. | Jun 2002 | A1 |
20020141964 | Patterson et al. | Oct 2002 | A1 |
20020197302 | Cochrum et al. | Dec 2002 | A1 |
20030018357 | Luthra et al. | Jan 2003 | A1 |
20030133990 | Hursey et al. | Jul 2003 | A1 |
20030165560 | Otsuka et al. | Sep 2003 | A1 |
20030175333 | Shefer et al. | Sep 2003 | A1 |
20030176828 | Buckman et al. | Sep 2003 | A1 |
20030181917 | Gertner | Sep 2003 | A1 |
20030199922 | Buckman | Oct 2003 | A1 |
20030208150 | Bruder et al. | Nov 2003 | A1 |
20030212357 | Pace | Nov 2003 | A1 |
20040005350 | Looney et al. | Jan 2004 | A1 |
20040013715 | Wnek et al. | Jan 2004 | A1 |
20040038893 | Ladner et al. | Feb 2004 | A1 |
20040121027 | Pushpangadan et al. | Jun 2004 | A1 |
20040121438 | Quirk | Jun 2004 | A1 |
20040131820 | Turner et al. | Jul 2004 | A1 |
20040166172 | Rosati et al. | Aug 2004 | A1 |
20040166758 | Reichmann et al. | Aug 2004 | A1 |
20040169033 | Kuibira et al. | Sep 2004 | A1 |
20040243043 | McCarthy et al. | Dec 2004 | A1 |
20050023956 | Kwak et al. | Feb 2005 | A1 |
20050058721 | Hursey | Mar 2005 | A1 |
20050070693 | Hansen et al. | Mar 2005 | A1 |
20050074505 | Hursey | Apr 2005 | A1 |
20050107826 | Zhu et al. | May 2005 | A1 |
20050118230 | Hill et al. | Jun 2005 | A1 |
20050119112 | Pfenninger et al. | Jun 2005 | A1 |
20050137512 | Campbell et al. | Jun 2005 | A1 |
20050143689 | Ramsey, III | Jun 2005 | A1 |
20050147656 | McCarthy et al. | Jul 2005 | A1 |
20050226911 | Bringley et al. | Oct 2005 | A1 |
20050246009 | Toner et al. | Nov 2005 | A1 |
20050248270 | Ghosh et al. | Nov 2005 | A1 |
20050249899 | Bonutti | Nov 2005 | A1 |
20050287239 | Joo et al. | Dec 2005 | A1 |
20060034935 | Pronovost et al. | Feb 2006 | A1 |
20060078628 | Koman et al. | Apr 2006 | A1 |
20060116635 | Van Heughten | Jun 2006 | A1 |
20060121101 | Ladizinsky | Jun 2006 | A1 |
20060127437 | Kennedy et al. | Jun 2006 | A1 |
20060141018 | Cochrum et al. | Jun 2006 | A1 |
20060141060 | Hursey et al. | Jun 2006 | A1 |
20060159733 | Pendharkar et al. | Jul 2006 | A1 |
20060172000 | Cullen et al. | Aug 2006 | A1 |
20060178609 | Horn et al. | Aug 2006 | A1 |
20060193905 | Ehringer et al. | Aug 2006 | A1 |
20060211965 | Horn et al. | Sep 2006 | A1 |
20060211971 | Horn et al. | Sep 2006 | A1 |
20060271094 | Hudson et al. | Nov 2006 | A1 |
20060282046 | Horn et al. | Dec 2006 | A1 |
20070004995 | Horn et al. | Jan 2007 | A1 |
20070016152 | Karpowicz et al. | Jan 2007 | A1 |
20070031515 | Stucky et al. | Feb 2007 | A1 |
20070065491 | Huey et al. | Mar 2007 | A1 |
20070104768 | Huey et al. | May 2007 | A1 |
20070104792 | Jenkins | May 2007 | A1 |
20070134293 | Huey et al. | Jun 2007 | A1 |
20070142783 | Huey et al. | Jun 2007 | A1 |
20070154509 | Wilcher et al. | Jul 2007 | A1 |
20070154510 | Wilcher et al. | Jul 2007 | A1 |
20070154564 | Stucky et al. | Jul 2007 | A1 |
20070160638 | Mentkow et al. | Jul 2007 | A1 |
20070160653 | Fischer et al. | Jul 2007 | A1 |
20070167971 | Huey et al. | Jul 2007 | A1 |
20070251849 | Lo et al. | Nov 2007 | A1 |
20070264315 | Fournie et al. | Nov 2007 | A1 |
20070275073 | Huey et al. | Nov 2007 | A1 |
20070276308 | Huey et al. | Nov 2007 | A1 |
20070276345 | Huey et al. | Nov 2007 | A1 |
20070281011 | Jenkins et al. | Dec 2007 | A1 |
20080027365 | Huey | Jan 2008 | A1 |
20080085300 | Huey et al. | Apr 2008 | A1 |
20080097271 | Lo et al. | Apr 2008 | A1 |
20080125686 | Lo | May 2008 | A1 |
20080131855 | Eggert et al. | Jun 2008 | A1 |
20080145455 | Bedard | Jun 2008 | A1 |
20080146984 | Campbell et al. | Jun 2008 | A1 |
20080154303 | Yassinzadeh | Jun 2008 | A1 |
20080199539 | Baker | Aug 2008 | A1 |
20080206134 | Lo et al. | Aug 2008 | A1 |
20080254146 | Huey et al. | Oct 2008 | A1 |
20080254147 | Huey et al. | Oct 2008 | A1 |
20080269658 | Vinton et al. | Oct 2008 | A1 |
20080299226 | Mentkow et al. | Dec 2008 | A1 |
20080317831 | Lo | Dec 2008 | A1 |
20080319476 | Ward et al. | Dec 2008 | A1 |
20090008261 | Kotzeva et al. | Jan 2009 | A1 |
20090011394 | Meglan et al. | Jan 2009 | A1 |
20090018479 | McCarthy et al. | Jan 2009 | A1 |
20090043268 | Eddy et al. | Feb 2009 | A1 |
20090047366 | Bedard et al. | Feb 2009 | A1 |
20090053288 | Eskridge, Jr. et al. | Feb 2009 | A1 |
20090074880 | Ladizinsky | Mar 2009 | A1 |
20090076475 | Ross et al. | Mar 2009 | A1 |
20090112170 | Wells et al. | Apr 2009 | A1 |
20090123525 | Bedard | May 2009 | A1 |
20090155342 | Diegelmann et al. | Jun 2009 | A1 |
20090162406 | Basadonna et al. | Jun 2009 | A1 |
20090186013 | Stucky | Jul 2009 | A1 |
20090186071 | Huey et al. | Jul 2009 | A1 |
20090232902 | Liu et al. | Sep 2009 | A1 |
20090274769 | Fregonese | Nov 2009 | A1 |
20090299253 | Hursey | Dec 2009 | A1 |
20100035045 | McAmish | Feb 2010 | A1 |
20100047352 | Pronovost et al. | Feb 2010 | A1 |
20100079395 | Kim et al. | Apr 2010 | A1 |
20100121244 | Horn et al. | May 2010 | A1 |
20100158989 | Mentkow et al. | Jun 2010 | A1 |
20100168767 | Yassinzadeh | Jul 2010 | A1 |
20100172958 | Lucchesi et al. | Jul 2010 | A1 |
20100184348 | McAmish | Jul 2010 | A1 |
20100209531 | Stucky et al. | Aug 2010 | A2 |
20100228174 | Huey | Sep 2010 | A1 |
20100233248 | Huey et al. | Sep 2010 | A1 |
20100292624 | Diegelmann et al. | Nov 2010 | A1 |
20100324464 | Kamakura et al. | Dec 2010 | A1 |
20110015565 | Hursey | Jan 2011 | A1 |
20110059287 | McAmish | Mar 2011 | A1 |
20110064785 | Daniels | Mar 2011 | A1 |
20110150973 | Bowlin et al. | Jun 2011 | A1 |
20110229849 | Maurer et al. | Sep 2011 | A1 |
20110237994 | Russ et al. | Sep 2011 | A1 |
20110268784 | Huey | Nov 2011 | A1 |
20120004636 | Lo | Jan 2012 | A1 |
20120045742 | Meglan et al. | Feb 2012 | A1 |
20120070470 | Pahari | Mar 2012 | A1 |
20120130296 | Huey | May 2012 | A1 |
20120259262 | Huey | Oct 2012 | A1 |
20130041332 | Huey | Feb 2013 | A1 |
20130060279 | Yassinzadeh | Mar 2013 | A1 |
20130079695 | Huey | Mar 2013 | A1 |
20130178778 | Huey | Jul 2013 | A1 |
20130267923 | Huey | Oct 2013 | A1 |
20130344131 | Lo | Dec 2013 | A1 |
20140171848 | Huey et al. | Jun 2014 | A1 |
20140377362 | Pahari | Dec 2014 | A1 |
20150141301 | Rovison, Jr. et al. | May 2015 | A1 |
20150209019 | Yassinzadeh | Jul 2015 | A1 |
20150221238 | Huebner | Aug 2015 | A1 |
20150250918 | Dubey | Sep 2015 | A1 |
20160120901 | Basadonna | May 2016 | A1 |
20160141018 | Lin et al. | May 2016 | A1 |
20160193380 | Dubey | Jul 2016 | A1 |
20160213808 | Huey | Jul 2016 | A1 |
20160256142 | Yassinzadeh | Sep 2016 | A1 |
20160345946 | Yassinzadeh et al. | Dec 2016 | A1 |
20170151365 | Dubey | Jun 2017 | A1 |
20170202546 | Yassinzadeh et al. | Jul 2017 | A1 |
20170296579 | Basadonna | Oct 2017 | A1 |
20180104378 | Huey | Apr 2018 | A1 |
20180221006 | Yassinzadeh | Aug 2018 | A1 |
20190167241 | Yassinzadeh et al. | Jun 2019 | A1 |
Number | Date | Country |
---|---|---|
1 223 208 | Jun 1987 | CA |
101104080 | Jan 2008 | CN |
201920992 | Aug 2011 | CN |
101687056 | Aug 2016 | CN |
0 107 051 | Sep 1983 | EP |
0 296 324 | Dec 1988 | EP |
0 353 710 | Feb 1990 | EP |
0 826 822 | Mar 1998 | EP |
0 888 783 | Jul 1999 | EP |
1 159 972 | May 2001 | EP |
1 714 642 | Oct 2006 | EP |
2 446 867 | May 2012 | EP |
548046 | Sep 1942 | GB |
2 175 889 | Dec 1986 | GB |
2 259 858 | Mar 1993 | GB |
2 314 842 | Jan 1998 | GB |
S59-62050 | Sep 1984 | JP |
61145120 | Jul 1986 | JP |
01-096558 | Oct 1987 | JP |
2-45040 | Feb 1990 | JP |
9-504719 | May 1997 | JP |
2777279 | Jul 1998 | JP |
10-337302 | Dec 1998 | JP |
11-071228 | Mar 1999 | JP |
11-178912 | Jul 1999 | JP |
11-332909 | Jul 1999 | JP |
2002-530157 | Sep 2002 | JP |
2002-331024 | Nov 2002 | JP |
2003-66045 | Mar 2003 | JP |
2003-305079 | Oct 2003 | JP |
2005-015537 | Jan 2005 | JP |
2004-123651 | Jul 2006 | JP |
WO 9219802 | Nov 1992 | WO |
WO 9505445 | Feb 1995 | WO |
WO 9512371 | May 1995 | WO |
WO 9640285 | Dec 1996 | WO |
WO 9913918 | Mar 1999 | WO |
WO 0030694 | Jun 2000 | WO |
WO 0066086 | Nov 2000 | WO |
WO 01082896 | Aug 2001 | WO |
WO 01097826 | Dec 2001 | WO |
WO 02030479 | Apr 2002 | WO |
WO 02060367 | Aug 2002 | WO |
WO 02074325 | Sep 2002 | WO |
WO 03057072 | Jul 2003 | WO |
WO 03074566 | Sep 2003 | WO |
WO 05012493 | Feb 2005 | WO |
WO 05030279 | Apr 2005 | WO |
WO 05087280 | Sep 2005 | WO |
WO 05123170 | Dec 2005 | WO |
WO 06006140 | Jan 2006 | WO |
WO 06012218 | Feb 2006 | WO |
WO 06088912 | Aug 2006 | WO |
WO 06110393 | Oct 2006 | WO |
WO 07120342 | Oct 2007 | WO |
WO 08036225 | Mar 2008 | WO |
WO 08054566 | May 2008 | WO |
WO 08109160 | Sep 2008 | WO |
WO 08127497 | Oct 2008 | WO |
WO 09109194 | Sep 2009 | WO |
WO 14047436 | Mar 2014 | WO |
Entry |
---|
US 9,730,957 B2, 08/2017, Basadonna et al. (withdrawn) |
Segal, H. C. et al., The Effects of Alginate and Non-Alginate Wound Dressings on Blood Coagulation and Platelet Activation, Journal of Biomaterials Applications, Jan. 1998, vol. 12, No. 3, pp. 249-257. |
Calcium Alginate, definition—Prepared at the 49th JECFA (1997), published in FNP 52 Add 5 (1997) superseding specifications prepared at the 44th JECFA (1995), published in FNP52, Add 3 (1995). An ADI ‘not specified’ was established at the 39th JECFA (1992). |
Kamala,et al.: “Extraction and Charactgerization of Water Soluble Chitosan from Parapeneopsis stylifera Shrimp Shell Waste and its Antibacterial Activity,” International Journal of Scientific and Research Publications, vol. 3, Issue 4, Apr. 2013. |
Qin, et al.: “Water-solubility of chitosan and its antimicrobial activity,” Carbohydrate Polymers 63 (2006) 367-374. |
Cease and Desist Letter from Z-Medica, LLC to Protégé Biomedical, LLC, dated Oct. 10, 2018 (21 pages). |
Plaintiff Protégé Biomedical, LLC's Complaint, dated Nov. 19, 2018 (“Complaint”), filed against Defendant Z-Medica, LLC, in Case No. 0:18-cv-03227 (12 pages). |
Plaintiff Protégé Biomedical, LLC's First Amended Complaint (and Exhibits A and B), dated Jan. 25, 2019 (“First Amended Complaint”), in Case No. 0:18-cv-03227 (156 pages). |
Defendant Z-Medica, LLC's Motion to Dismiss Plaintiff's First Amended Complaint, dated Feb. 7, 2019 in Case No. 0:18-cv-03227 (2 pages). |
Defendant Z-Medica, LLC's Memorandum of Law in Support of Defendant's Motion to Dismiss Plaintiff's First Amended Complaint, dated Feb. 7, 2019 in Case No. 0:18-cv-03227 (35 pages). |
Declaration of Dina Dubey submitted with Memorandum of Law in Support of Defendant's Motion to Dismiss Plaintiff's First Amended Complaint, dated Feb. 7, 2019 in Case No. 0:18-cv-03227 (5 pages). |
Plaintiff Protégé Biomedical, LLC's Response Memorandum of Law in Opposition to Defendant's Motion to Dismiss Under Fed. R. Civ. P. 12(B)(2) and 12(B)(6), dated Feb. 28, 2019, in Case No. 0:18-cv-03227 (48 pages). |
Defendant Z-Medica, LLC's Reply in Support of Defendant's Motion to Dismiss Plaintiff's First Amended Complaint, dated Mar. 14, 2019 in Case No. 0:18-cv-03227 (20 pages). |
Declaration of Dina Dubey submitted with Reply in Support of Defendant's Motion to Dismiss Plaintiff's First Amended Complaint, dated Mar. 14, 2019 in Case No. 0:18-cv-03227 (2 pages). |
Plaintiff Protégé Biomedical, LLC's Motion for Injunctive Relief and Expedited Handling of the Case, dated Dec. 12, 2018, in Case No. 0:18-cv-03227 (4 pages). |
Plaintiff Protégé Biomedical, LLC's Memorandum of Law in Support of Protégé Biomedical's Motion for Injunctive Relief and Expedited Handling of the Case, dated Dec. 12, 2018, in Case No. 0:18-cv-03227 (34 pages). |
Declaration of Susan Wuollett submitted with Memorandum of Law in Support of Protégé Biomedical's Motion for Injunctive Relief and Expedited Handling of the Case, dated Dec. 12, 2018, in Case No. 0:18-cv-03227 (8 pages). |
Plaintiff Protégé Biomedical, LLC's Notice of Withdrawal of Plaintiff's Motion for Injunctive Relief Filed Dec. 12, 2018 Without Prejudice, dated Jan. 14, 2019, in Case No. 0:18-cv-03227 (3 pages). |
A Rule 26(f) Pretrial Conference Report and its Exhibits, dated Feb. 26, 2019, in Case No. 0:18-cv-03227 (28 pages). |
A Docket Report from Mar. 21, 2019, in Case No. 0:18-cv-03227 (9 pages). |
Pretrial Scheduling Order, Dated Filed Mar. 26, 2019 in Case 0:18-cv-03227-JRT-HB; pp. 1-19. |
Defendant Z-Medica, LLC's Memorandum in Support of D's First Motion to Compel, dated Apr. 22, 2019, in Case No. 0:18-cv-03227 (32 pages). |
Dec of Charles Nauen in Support of Defendant Z-Medica, LLC's Memorandum in Support of D's First Motion to Compel, dated Apr. 22, 2019, in Case No. 0:18-cv-03227 (2 pages). |
Exhibits A-C for Dec of Charles Nauen in Support of Defendant Z-Medica, LLC's Memorandum in Support of D's First Motion to Compel, dated Apr. 22, 2019, in Case No. 0:18-cv-03227 (73 pages). |
Exhibit D for Dec of Charles Nauen in Support of Defendant Z-Medica, LLC's Memorandum in Support of D's First Motion to Compel, dated Apr. 22, 2019, in Case No. 0:18-cv-03227 (31 pages). |
Exhibit E for Dec of Charles Nauen in Support of Defendant Z-Medica, LLC's Memorandum in Support of D's First Motion to Compel, dated Apr. 22, 2019, in Case No. 0:18-cv-03227 (6 pages). |
Exhibit F for Dec of Charles Nauen in Support of Defendant Z-Medica, LLC's Memorandum in Support of D's First Motion to Compel, dated Apr. 22, 2019, in Case No. 0:18-cv-03227 (16 pages). |
Exhibit G for Dec of Charles Nauen in Support of Defendant Z-Medica, LLC's Memorandum in Support of D's First Motion to Compel, dated Apr. 22, 2019, in Case No. 0:18-cv-03227 (55 pages). |
Plaintiff Protégé Biomedical, LLC's Motion to Compel, dated Apr. 22, 2019, in Case No. 0:18-cv-03227 (21 pages). |
Dec of Laura Conley in Support of Plaintiff Protégé Biomedical, LLC's Motion to Compel, dated Apr. 22, 2019, in Case No. 0:18-cv-03227 (3 pages). |
Exhibit C for Dec of Laura Conley in Support of Plaintiff Protégé Biomedical, LLC's Motion to Compel, dated Apr. 22, 2019, in Case No. 0:18-cv-03227 (7 pages). |
Exhibit D for Dec of Laura Conley in Support of Plaintiff Protégé Biomedical, LLC's Motion to Compel, dated Apr. 22, 2019, in Case No. 0:18-cv-03227 (31 pages). |
Exhibit E for Dec of Laura Conley in Support of Plaintiff Protégé Biomedical, LLC's Motion to Compel, dated Apr. 22, 2019, in Case No. 0:18-cv-03227 (30 pages). |
Exhibit F for Dec of Laura Conley in Support of Plaintiff Protégé Biomedical, LLC's Motion to Compel, dated Apr. 22, 2019, in Case No. 0:18-cv-03227 (20 pages). |
Exhibit I for Dec of Laura Conley in Support of Plaintiff Protégé Biomedical, LLC's Motion to Compel, dated Apr. 22, 2019, in Case No. 0:18-cv-03227 (3 pages). |
Exhibit J for Dec of Laura Conley in Support of Plaintiff Protégé Biomedical, LLC's Motion to Compel, dated Apr. 22, 2019, in Case No. 0:18-cv-03227 (3 pages). |
Exhibit K for Dec of Laura Conley in Support of Plaintiff Protégé Biomedical, LLC's Motion to Compel, dated Apr. 22, 2019, in Case No. 0:18-cv-03227 (16 pages). |
Exhibit L for Dec of Laura Conley in Support of Plaintiff Protégé Biomedical, LLC's Motion to Compel, dated Apr. 22, 2019, in Case No. 0:18-cv-03227 (6 pages). |
Exhibit N for Dec of Laura Conley in Support of Plaintiff Protégé Biomedical, LLC's Motion to Compel, dated Apr. 22, 2019, in Case No. 0:18-cv-03227 (5 pages). |
Defendant Z-Medica, LLC's Opposition to Plaintiff's Motion to Compel, dated Apr. 23, 2019, in Case No. 0:18-cv-03227 (3 pages). |
Plaintiff Protégé Biomedical, LLC's Combined Response Reply Brief on Motions to Compel, dated Apr. 30, 2019, in Case No. 0:18-cv-03227 (15 pages). |
Plaintiff Protégé Biomedical, LLC's Interrogatory Responses, dated Apr. 30, 2019, in Case No. 0:18-cv-03227 (51 pages). |
Plaintiff Protégé Biomedical, LLC's Memorandum in Support of Leave to Amend Complaint, dated May 3, 2019, in Case No. 0:18-cv-03227 (6 pages). |
Dec of Joseph Balthazor for in Support of Plaintiff Protégé Biomedical, LLC's Memorandum in Support of Leave to Amend Complaint, dated May 3, 2019, in Case No. 0:18-cv-03227 (3 pages). |
Plaintiff Protégé Biomedical, LLC's Second Amended Complaint, dated May 3, 2019, in Case No. 0:18-cv-03227 (48 pages). |
A Docket Report from May 6, 2019, in Case No. 0:18-cv-03227. |
Order Approving Stipulation to Stay Pending Ruling on Motion to Dismiss, dated May 27, 2019, in Case No. 0:18-cv-03227 (1 page). |
Opinion and Order Regarding Defendant Z-Medica's Motion to Dismiss, dated Jul. 24, 2019, in Case No. 0:18 cv-03227 (29 pages). |
Defendant Z-Medica LLC's Answer to Amended Complaint, dated Aug. 21, 2019, in Case No. 0:18 cv-03227 (67 pages). |
Plaintiff Protege Biomedical, LLC's Reply and Affirmative Defenses, dated Sep. 11, 2019, in Case No. 0:18-cv-03227 (8 pages). |
Settlement Conference Minutes, dated Sep. 18, 2019, in Case No. 0:18-cv-03227 (2 pages). |
A Docket Report from Sep. 24, 2019, in Case No. 0:18-cv-03227 (18 pages). |
“Mastering the Art of Innovative Thinking,” (color brochure) FMC BioPolymer, 2001 FMC Corporation. |
Acheson, et al.: “Comparison of Hemorrage Control Agents Applied to Lethal Extremity Arterial Hemorrages in Swine,” The Journal of Trauma, Injury, Infection, and Critical Care, 2005:59 865-875. |
Alam, et al., Application of a Zeolite Hemostatic Agent Achieves 100% Survival in a Lethal Model of Complex Groin Injury in Swine, May 2004, The Journal of Trauma Injury, Infection, and Critical Care, vol. 56, pp. 974-983. |
Alam, et al., Comparative Analysis of Hemostatic Agents in a Swine Model of Lethal Groin Injury, Jun. 2003, The Journal of Trauma Injury, Infection, and Critical Care, vol. 54, No. 6, pp. 1077-1082. |
Aldrich—Handbook of Fine Chemicals and Laboratory Equipment, 2000-2001, pp. 1177-1178. |
Analgesics and Anti-inflammatory agents 2004, retrieved from the internet on May 26, 2010, URL: http://web.archive.org/web/20040904151322/http://faculty.weber.edu/ewalker/Medicinal_Chemistry/topics/Analgesia_antiinflam/Analgesics_anti-inflammatory.htm. |
Angeloni, V., M.D.: “How to care for your wound.”, Heartland Dermatology & Skin Cancer P.C., copyright 2001, V. Angeloni MD. |
Army halts use of new first aid item to study more, Seattle PI, Dec. 24, 2008. |
Army halts use of WoundStat, http://stripes.com, Apr. 23, 2009. |
Army pulls anti clotting agent after Fort Sam study finds threat, MySanAntonio Military, Dec. 24, 2008. |
Baker, Sarah E. et al., Controlling Bioprocesses with Inorganic Surfaces: Layered Clay Hemostatic Agents, Department of Chemistry and Biochemistry, University of California, Santa Barbara, American Chemical Association 2007, 19, pp. 4390-4392 (3 pages total). |
Basadonna, G., et al.: “A novel kaolin coated surgical gauze improves hemostasis both in vitro and in vivo”, Journal of Surgical Research, vol. 144, No. 2, Feb. 2008, p. 440, XP002534658, abstract. |
Bethesda, MD, TraumaCure, Life-saving News for Battlefield Soldiers & Wounded Civilians FDA Clears Product to Stop Severe Bleeding, Sep. 10, 2007. |
Butenas—Mechanism of factor VIIa-dependent coagulation in hemophilia blood, Hemostasis, Thrombosis, and Vascular Biology, Blood, Feb. 1, 2002—vol. 99, No. 3. |
Caloplast (Kaolin Poultrice), South African Electronic Package Inserts, Information presented by Malahide Information Systems, Copyright 1996-1998, printed from home.intekom.com/pharm/allied/caloplst.html#INDICATIONS, two pages. |
Carraway, et al., Comparison of a new mineral based hemostatic agent to a commercially available granular zeolite agent for hemostasis in a swine model of lethal extremity arterial hemorrhage, Resuscitation vol. 78, Issue 2. |
Clay makers (raw materials) retrieved from the internet on Mar. 15, 2010, URL: http://web.archive.org/web/20020609175053/http://www.claymaker.com/ceramic_central/info/raw_clays.htm (year 2002, pp. 104). |
Comparative Testing of Hemostatic Dressings in a Severe Groin Hemorrhage, Trauma & Resuscitative Medicine Department, NMRC, Aug. 2008 (Part 2 of 3, pp. 10-19). |
Comparative Testing of Hemostatic Dressings in a Severe Groin Hemorrhage, Trauma & Resuscitative Medicine Department, NMRC, Aug. 2008 (Part 3 of 3, pp. 20-29). |
Comparative Testing of Hemostatic Dressings in a Severe Groin Hemorrhage, Trauma &Resuscitative Medicine Department, NMRC, Aug. 2008 (Part 1 of 3, pp. 1-9). |
Connor, William E.: “The Acceleration of Thrombus Formatin by Certain Fatty Acids,” Journal of Clinical Investigation, vol. 41, No. 6, 1962. |
Curasorb Calcium Alginate Dressings information page, http://www.kendallhq.com/kendallhealthcare/pageBuilder.aspx?webPageID=0&topicID=70966&xsl=xsl/productPagePrint.xsl (last accessed May 22, 2012). |
Davis et al., 1H—NMR Study of Na Alginates Extracted from Sargassum spp. in Relation to Metal Biosorption, 110 Applied Biochemistry and Biotechnology 75 (2003). |
Dictionary of Traditional Chinese Medicine, “Astringents and Haemostatices,” The Commercial Press, LTD., Apr. 1984 [ISBN 962 07 3051 8], pp. 216-217, total 4 pages. |
Dubick et al.: “New Technologies for Treating Severe Bleeding in Far-Forward Combat Areas,” RTO-MP-HFM-182, 21-1 to 21-12. NATO/OTAN, US Army Institute of Surgical Research. |
Dyer, A. et al. “Diffusion in heteroionic zeolites: part 1. Diffusion of water in heteroionics natrolites.” Microporous and Mesoporous Materials. 1998. pp. 27-38. vol. 21. |
EPO Extended Search Report, re EP Application No. 12163455, dated Sep. 12, 2012. |
Fruijtier-Polloth, “The safety of synthetic zeolites used in detergents”, Arch Toxicol (2009) 83:23-25. |
Galan, et al.: “Technical properties of compound kaolin sample from griva (Macedonia, Greece)”, Applied Clay Science 1996 10:477-490. |
Gibbar-Clements, et al.: “The Challenge of Warfarin Therapy”, JSTOR: The American Journal of Nursing,vol. 100, No. 3 (Mar. 2000), pp. 38-40. |
Gielen, M., Solid State Organometallic Chemistry: Methods and Applications Physical Organometallic Chemistry, 1999, New York John Wiley & Sons, Ltd. (UK), V. 2, p. 156. |
Griffin, J. H.: “Role of surface in surface-dependent activation of Hageman factor (blood coagulation Factor XII)”, Proc. Natl. Acad. Sci, USA, vol. 75, No. 4, pp. 1998-2002, Apr. 1978 Medical Sciences. |
Griffin, John H., Role of surface in surface-dependent activation of Hageman factor (blood coagulation Factor XII), Proc. Natl. Acad. Sci. USA, vol. 75, No. 4, Apr. 1978, pp. 1998-2002 (5 pages total). |
Hahn, Lynn: “High temperature 1H NMR to determine the relative amounts of guluronate and mannuronate in the sodium alginate sample”, Intertek, ASA, Analytical Report, Report No. 60665 v 1, dated May 6, 2012. |
Handbook of textile fibre structure, First Published 2009, p. 276, Par. 1. (1 page). |
HemCon Medical Technologies Inc. 501(k) Summary, ChitoGauze, Mar. 20, 2009. |
Hempen, et al., A Materia Medica for Chinese Medicine, Plants minerals and animal products, Churchill Livingston Elsevier, 2009, [ISBN 978 0 443 10094 9], pp. 832-833 (Halloysitum rubrum, Chi shi zi), total 5 pages. |
Hollister Wound Care Restore Calcium Alginate Dressing, Silver instruction manual and information booklet, available at http://hollisterwoundcare.com/files/pdfs/ifus/Restore907814B407ColorBreak.pdf (last accessed May 22, 2012). |
Hsu, et al.: Oriental Materia Medica a concise guide. 1986 by the Oriental Healing Arts Institute. |
Huang: The Pharmacology of Chinese Herbs, Second Edition. 1999 by CRC Press LLC. |
Hubbard, et al.: “Ionic charges of glass surfaces and other materials, and their possible role in the coagulation of blood,” Journal of Applied Physiology, Mar. 1, 1960, vol. 15, No. 2, pp. 265-270. |
IMA-EU, Kaolin, Oct. 2006, p. 1-2. |
International Report on Patentability and Written Opinion re PCT/US2009/040256, dated Oct. 12, 2010. |
International Preliminary Report and Written Opinion for Application No. PCT/US2007/023265, dated Sep. 29, 2009. |
International Preliminary Report and Written Opinion for PCT/US2004/029809, dated Mar. 13, 2006. |
International Preliminary Report and Written Opinion re PCT/US2006/004594, dated Aug. 14, 2007. |
International Preliminary Report and Written Opinion re PCT/US2008/006517, dated Nov. 24, 2009. |
International Preliminary Report and Written Opinion Report for Application No. PCT/US2008/060177, dated Oct. 13, 2009. |
International Report on Patentability and Written Opinion for Application No. PCT/US2008/003082, dated Sep. 29, 2009. |
International Search Report for Application No. PCT/US2004/029812, dated Jun. 14, 2005. |
International Search Report for Application No. PCT/US2006/004594, dated Nov. 3, 2006. |
International Search Report for Application No. PCT/US2006/012487, dated Sep. 12, 2006. |
International Search Report for Application No. PCT/US2007/016509, dated Feb. 8, 2008. |
International Search Report for Application No. PCT/US2007/023265, dated Sep. 17, 2009. |
International Search Report for Application No. PCT/US2008/003082, dated Sep. 24, 2009. |
International Search Report for Application No. PCT/US2008/060177, dated Jun. 22, 2009. |
International Search Report for Application No. PCT/US2008/075191, dated Oct. 6, 2008. |
International Search Report for PCT/US2004/029809, dated Feb. 24, 2005. |
International Search Report for PCT/US2005/046700, dated Jul. 6, 2006. |
International Search Report re Application No. PCT/US2010/041741, dated Nov. 26, 2010. |
International Search Report re PCT/US2009/040256, dated Aug. 4, 2009. |
James, “Silver Copper Zeolite Guinea Pig Sensitization Study—Buehler Method”, Data Evaluation Report dated Oct. 3, 1989. |
Kheirabadi, Army Assessment of New Hemostatic Products Suitable for Treating Combat Wounds, US Army Institute of Surgical Research, Aug. 11, 2008. |
Kheirabadi, et al., Session IV-B, Paper 28, 8:20 a.m., Comparison of New Hemostatic Dressings with Currently Deployed Hemcon Bandage in a Model of Extremity Arterial Hemorrhage in Swine. |
Kheirabadi, et al., The Journal of Trauma Injury, Infection, and Critical Care, Comparison of New Hemostatic Granules/Powders with Currently Deployed Hemostatic Products in a Lethal model of Extremity Arterial Hemorrhage in Swine, Feb. 2009, pp. 316-328. |
Kheirabadi, Final Report, Title: Assessment of Efficacy of New Hemostatic Agents in a Model of Extremity Arterial Hemorrhage in Swine, U.S. Army Institute of Surgical Research, Ft. Sam Houston, TX 78234, Mar. 4, 2008. |
Kovzun, I. G., et al.: “Application of nanosize clay-mineral systems in the complex therapy for hemophilia “A” patients”, Database HCAPLUS [online], XP002534657, retrieved from STN Database accession No. 2009:502758 abstract & Nanosistemi, Nanomateriali, Nanotekhnologii, vol. 6, No. 2, 2008. |
Le Van Mao, Raymond et al. “Mesoporous Aluminosilicates prepared from Zeolites by Treatment with Ammonium Fluorosilicate.” J. Mater. Chem. 1993. pp. 679-683. vol. 3, No. 6. |
Li et al.: “Herbs for Promoting Astriction,” Chinese Materia Medica Combinations and Applications, Chapter 18, p. 622. 2002. |
Lin et al., Synthesis of Hybridized Polyacrylic Acid-Kaolin Material and its Superwater Absorbent Performance, J. Huaqiao Univ. (Nat. Sci.) Mar. 2000. |
Long et al., Synthesis of Bentonite-superabsorbent Composite, J. Guilin Inst. Tech., Feb. 2004. |
Macrina, VCU's Research Enterprise, Structure and Resources, Oct. 23, 2008. |
Manugel® GMB alginate, FMC BioPolymer, Know how. It works.sm Product Specifications, 2011 FMC Corporation. |
Margolis, “Initiation of Blood Coagulation by Glass and Related Surfaces”, J. Physiol. (1957) 137, 95-109. |
Margolis, J., The Kaolin Clotting Time: A Rapid One-Stage Method for Diagnosis of Coagulation Defects, J. Clin. Pathol 1958, 11, pp. 406-409 (5 pages total). |
Medline Maxorb Extra AG Silver Alginate, http://www.medicaldepartmentstore.com/Medline-Maxorb-p/1560.htm (last accessed May 22, 2012). |
Miyajima, C., General Information on Alginates and its Applications, Sen'i Gakkaishi (Fibers and Industry), 2009, pp. 444-448, vol. 65, No. 12. |
Oh, Seung-Taek et al.: “The Preparation of Plyurethane Foam Combined with pH-sensitive Alginate/Bentonite Hydrogel for Wound Dressings,” Fibers and Polymers 2011, vol. 12. No. 2, 159-165. |
Okada, et al.: “Preparation of zeolite-coated cordierite honeycombs prepared by an in situ crystallization method”, Science and Technology of Advanced Materials 2004 5:479-484. |
O'Reilly et al.: “Studies on Coumarin Anticoagulant Drugs—Initiation of Warfarin Therapy Without a Loading Dose”, Circulation by the American Heart Association, http://circ.ahajournals.org, 1968, 38, 169-177. |
Ore-Medix, Traumastat Hemostatic Bandage, Aug. 7, 2008. |
Permanent suspension of Woundstat use, https://email.z-medica.com, Apr. 17, 2009. |
Pusateri, et al.: “Application of a Granular Mineral-Based Hemostatic Agent (QuickClot) to Reduce Blood Loss After Grade V Liver Injury in Swine,” The Journal of Trauma, Injuary, Infection, and Critical Care, 2004:57 555-562. |
Pusateri, et al.: “Effect of a Chitosan-Based Hemostatic Dressing on Blood Loss and Survival in a Model of Sever Henous Hemorrage and Hepatic Injury in Swine,” The Journal of Trauma, Injury, Infection, and Critical Care, 2003: 54 177-182. |
Reprinted related contents of U.S. Abstract regarding QuikClot Combat Gauze, Apr. 2009. |
Reprinted related contents of US Alaract regarding QuikClot CombatGauze, Sep. 2008. |
Revised Pharmaceutical Product Additive Handbook, Yakuji Hosha Inc., Feb. 28, 2007, first printing, p. 41-44 (publication showing well-known technology). |
Ross, et al., “The Kaolin Minerals,” J. Amer. Ceramic Soc., vol. 13, issue 3, pp. 151 to 160, Mar. 1930. |
Sadler et al.: “Biochemistry and Genetics of Van Willebrand Factor”, Annual Review of Biochemistry; 1998. 67:395-424. |
Scott Sackinger's Medical Devices Professional Summary dated Mar. 2009. |
Sinter. (2004). In The New Penguin Dictionary of Science. London: Penguin. Retrieved May 7, 2009, from http://www.credoreference.com/entry/7463549/. |
Soine et al., Rogers Inorganic Pharmaceutical Chemistry, Lea & Febiger 1967, p. 462-463 (Aluminum and Aluminum Compounds), [QV744 S683r 1967] total 5 pages. |
Stasilon, Wikipedia—definiation 2011. |
Tactical Combat Casualty Care Guidelines, Feb. 2009. |
The Merck Index; 1989, pp. 1596-1597, abstract 10021. |
Top, Ayben et al. “Silver, zinc, and copper exchange in a Na-clinoptilolite and resulting effect on antibacterial activity.” Applied Clay Science. 2004. pp. 13-19. vol. 27. |
Traditional Chinese Medicine, A Manual from A-Z. Symptoms, Therapy and Herbal Remedies. Springer-Verlag Berlin Heidelberg 2003. |
TraumaCure, Innovative Wound Care Products for Wound Care Solutions, Apr. 24, 2009. |
U.S. Appl. No. 13/598,381, filed Aug. 29, 2012, including prosecution history. |
U.S. Appl. No. 13/595,932, filed Aug. 27, 2012, including prosecution history. |
U.S. Office Action re U.S. Appl. No. 11/634,673, filed Dec. 5, 2006, Office Action dated May 21, 2009. |
U.S. Appl. No. 13/593,310, filed Aug. 23, 2012, including prosecution history. |
U.S. Appl. No. 13/911,616, filed Jun. 6, 2013, including prosecution history. |
U.S. Appl. No. 13/682,085, filed Nov. 20, 2012, including prosecution history. |
U.S. Appl. No. 13/759,963, filed Feb. 5, 2013, including prosecution history. |
U.S. Appl. No. 15/090,072, filed Apr. 4, 2016 including prosecution history. |
U.S. Appl. No. 12/140,356, filed Jun. 17, 2008 including prosecution history. |
U.S. Appl. No. 15/641,999, filed Jul. 5, 2017 including prosecution history. |
U.S. Appl. No. 13/175,380, filed Jul. 1, 2011, including prosecution history. |
U.S. Appl. No. 13/922,115, filed Jun. 19, 2013, including prosecution history. |
U.S. Appl. No. 15/071,520, filed Mar. 16, 2016, including prosecution history. |
U.S. Appl. No. 15/429,935 filed Feb. 10, 2017 including prosecution history. |
U.S. Appl. No. 14/643,689, filed Mar. 10, 2015, including prosecution history. |
U.S. Office Action re U.S. Appl. No. 11/398,161 dated Apr. 30, 2008. |
U.S. Appl. No. 12/352,513, filed Jan. 12, 2009 including prosecution history. |
U.S. Appl. No. 60/668,022, filed Apr. 4, 2005, including prosecution history. |
U.S. Appl. No. 60/708,206, filed Aug. 15, 2005, including prosecution history. |
U.S. Appl. No. 60/902,738, filed Feb. 21, 2007, including prosecution history. |
U.S. Appl. No. 60/955,854, filed Aug. 14, 2007, including prosecution history. |
Vitrify—(2001). In Chambers 21st Century Dictionary. London. Chambers Harrap. Retrieved May 7, 2009, from http://www.credoreference.com/entry/1236485/. |
Vlok, Marie E.: “Kaolin poultice”, Manual of Nursing, vol. 1, Basic Nursing, revised ninth edition, p. 269. Copyright Juta & Co, Ltd., Lansdowne, South Africa, first published 1962. |
Voet, Donald & Judith: “Molecular Physiology”, Biochemistry, p. 1087-1096, vol. 64, 1990, John Wiley & Sons. |
Wagner, Holly, “Topical Oxygen Helps Hard-To-Heal Wounds Heal Faster and Better,” Jan. 28, 2003, obtained from http://researchnews.osu.edu/archive/oxywound.htm. |
Ward, et al., The Journal of Trauma Injury, Infection, and Critical Care, Comparison of a New Hemostatic Agent to Current Combat Hemostatic Agents in a Swine Model of Lethal Extremity Arterial Hemorrhage, Aug. 2007, pp. 276-284. |
Ward, Declaration and CV, signed Jul. 19, 2012. |
Webster's Dictionary definition of “expose” (1993). |
Wound Stat, http://shadowspear.com/vb/showthread.php?t=16586 dated Dec. 22, 2008, last accessed Apr. 16, 2009. |
WoundStat found to be potentially hazardous, Army News, news from Iraq . . . , http://armytimes.com/news/2009/04/army_woundstat_042009w/, posted Apr. 20, 2009, last accessed Apr. 20, 2009. |
Wright, J. Barry et al.: “Wound management in an era of increasing bacterial antibiotic resistance: A role for topical silver treatment”, American Journal of Infection Control, vol. 26 (6), 1998, pp. 572-577. |
Wright, J.K. et al. “Thermal Injury Resulting from Application of a GranularMineral Hemostatic Agent.” The Journal of Trauma Injury, Infection, and Critical Care. 2004. pp. 224-230. vol. 57, No. 2. |
Wu, Jing-Nuan, “An Illustrated Chinese Materia Medica,” Oxford University Press, Inc. 2005 (13 pages). |
Xinrong, Traditional Chinese Medicine, A Manual from A-Z, Symptoms, Therapy and Herbal Remedies, [ISBN 3 540 42846 1], p. 470 (total 3 pages), Springer-Verlag Berlin Heidelberg 2003. |
Yanchi, The Essential Book of Traditional Chinese Medicine, vol. 2: Clinical Practice, p. 155-157 (Traditional Chinese Prescriptions), 142-143 (Chinese Medicinal Herbs) total 8 pages. [ISBN 0 231 06518 3 9v.2] 1988. |
Yanchi, Liu: “Drug Forms: Their Administration and Actions,” The Essential Book of Traditional Chinese Medicine 7, vol. 2: Clinical Practice. 1988. |
Z-Medica Corporation 510(k) Summary, QuikClot eX, Oct. 4, 2007. |
Le et al.: “Recent development in fibres and materials for wound management,” Indian Journal of Fibre & Textile Research, 1997. |
Protégé Biomedica, LLC Invalidity Contentions of Z-Medica, Llc U.S. Pat. No. 10,086,106, in Case No. 0:18-cv-03227, dated Oct. 11, 2019 (363 pages). |
Defendant Z-Medica LLC's Motion for Leave to Amend Initial Infringement Claim Charts date Nov. 8, 2019, in Case No. 0:18 cv-03227 (2 pages). |
Defendant Z-Medica LLC's Response to Protégé Biomedical, LLC's Invalidity Contentions Regarding U.S. Pat. No. 10,086,106, in Case No. 0:18-cv-03227, (251 pages). |
Joint Claim Construction Statement, dated Nov. 13, 2019, in Case No. 0:18-cv-03227 and Exhibits A-F thereof (28 pages). |
Plaintiff Protege Biomedical, LLC's Response Memorandum in Opposition to Z-Medica, LLC's Motion for Leave to Amend Initial Infringement Claim Charts, dated Nov. 15, 2019, in Case No. 0:18-cv-03227 (8 pages). |
Declaration of Andrew S. Dosdall in Support of Defendant's Motion for Leave to Amend initial Infringement Claim Charts, dated Nov. 15, 2019 (2 pages). |
Statement Regarding Exhibit A Accompanying Declaration of Andrew S. Dosdall, dated Nov. 15, 2019 (2 pages). |
A Docket Report from Dec. 16, 2019, in Case No. 0:18-cv-03227 (25 pages). |
A Docket Report from Dec. 23, 2019, in Case No. 0:18-cv-03227 (21 pages). |
Joint Claim Construction Statement, dated Jan. 15, 2020, in Case No. 0:18-cv-03227 (11 pages). |
Counterclaim Plaintiff Z-Medica, LLC's Opening Claim Construction Brief, dated Jan. 27, 2020, in Case No. 0:18-cv-03227 (17 pages). |
Declaration of Ali Razai and Exhibits in Support of Counterclaim Plaintiff Z-Medica, LLC's Claim Construction Brief, dated Jan. 27, 2020, in Case No. 0:18-cv-03227 (167 pages). |
Declaration of Douglas Loy and Exhibits in Support of Counterclaim Plaintiff Z-Medica, LLC's Claim Construction Brief, dated Jan. 27, 2020, in Case No. 0:18-cv-03227 (44 pages). |
Plaintiff Protégé Biomedical, LLC's Opening Claim Construction Brief, dated Jan. 27, 2020, in Case No. 0:18-cv-03227 (39 pages). |
Declaration of Andrew Dosdall and Exhibits in Support of Plaintiff Protégé Biomedical, LLC's Opening Claim Construction Brief, dated Jan. 27, 2020, in Case No. 0:18-cv-03227 (88 pages). |
Plaintiff Protégé Biomedical, LLC's Motion to Compel, dated Jan. 30, 2020, in Case No. 0:18-cv-03227 (2 pages). |
Plaintiff Protégé Biomedical, LLC's Memorandum in Support of Motion to Compel, dated Jan. 30, 2020, in Case No. 0:18-cv-03227 (20 pages). |
Declaration of Balthazor and Exhibits in Support of Plaintiff Protégé Biomedical, LLC's Motion to Compel, dated Jan. 30, 2020, in Case No. 0:18-cv-03227 (25 pages). |
Defendant Z-Medica, LLC's Motion to Compel, dated Jan. 31, 2020, in Case No. 0:18-cv-03227 (2 pages). |
Defendant Z-Medica, LLC's Memorandum in Support of Motion to Compel, dated Jan. 30, 2020, in Case No. 0:18-cv-03227 (35 pages). |
Declaration of Charles Nauen and Exhibits in Support of Defendant Z-Medica, LLC's Motion to Compel, dated Jan. 30, 2020, in Case No. 0:18-cv-03227 (25 pages). |
Defendant Z-Medica, LLC's Opposition to P's Motion to Compel, dated Feb. 6, 2020, in Case No. 0:18-cv-03227 (48 pages). |
Plaintiff Protégé Biomedical, LLC's Opposition to D's Motion to Compel, dated Feb. 7, 2020, in Case No. 0:18-cv-03227 (26 pages). |
Exhibit for Plaintiff Protégé Biomedical, LLC's Opposition to D's Motion to Compel, dated Feb. 7, 2020, in Case No. 0:18-cv-03227 (26 pages). |
Plaintiff Protégé Biomedical, LLC's Responsive Claim Construction Brief, dated Feb. 10, 2020, in Case No. 0:18-cv-03227 (10 pages). |
Counterclaim Plaintiff Z-Medica, LLC's Responsive Claim Construction Brief, dated Feb. 10, 2020, in Case No. 0:18-cv-03227 (35 pages). |
Second Declaration of Ali Razai in Support of Counterclaim Plaintiff Z-Medica, LLC's Responsive Claim Construction Brief, dated Feb. 10, 2020, in Case No. 0:18-cv-03227 (4 pages). |
Declaration of Andrew Dosdall and Exhibits in Opposition of Defendant Z-Medica, LLC's Second Motion to Compel, dated Feb. 18, 2020, in Case No. 0:18-cv-03227 (12 pages). |
Letter to Magistrate Judge Regarding Defendant Z-Medica, LLC's Second Motion to Compel dated Feb. 21, 2020, in Case No. 0:18-cv-03227 (3 pages). |
Third Amended pretrial Case Management Order, dated Feb. 21, 2020, in Case No. 0:18-cv-03227 (22 pages). |
Plaintiff Protégé Biomedical, LLC's Memorandum of Law in Support of Leave to Amend First Amended Complaint, dated Mar. 2, 2020, in Case No. 0:18-cv-03227 (15 pages). |
Declaration Balthazor of in Support of Plaintiff Protégé Biomedical, LLC's Memorandum of Law in Support of Leave to Amend First Amended Complaint dated Mar. 2, 2020, in Case No. 0:18-cv-03227 (187 pages). |
Exhibit a to Balthazor Declaration for Plaintiff Protégé Biomedical, LLC's Second Amended Complaint, dated Mar. 3, 2020, in Case No. 0:18-cv-03227 (183 pages). |
A Docket Report from Mar. 13, 2020, in Case No. 0:18-cv-03227 (33 pages). |
Order denying Plaintiff's Motion to Compel Discovery, and granting Defendant's request for sanctions as to the cost of Z-Medica's reasonable fees and expenses incurred in opposing the motion, but denied as to any further relief, dated Mar. 17, 2020, in Case No. 0:18-cv-03227 (13 pages). |
Declaration of Charles N. Nauen (and Exhibits) in Support of Defendant's Opposition to Protégé's Third Motion to Compel, dated Jun. 15, 2020, in Case No. 0:18-cv-03227 (42 pages). |
Defendant Z-Medica's Response to Protégé's Objections to the Magistrate Judge's Order on Its Motion to for leave to Amend its First Amended Complaint, dated Jun. 23, 2020, in Case No. 0:18-cv-03227 (15 pages). |
Memorandum Opinion and Order Affirming Magistrate Judge Order and overruling 316 Objection by Protege Biomedical, LLC, dated Jul. 6, 2020, in Case No. 0:18-cv-03227 (8 pages). |
A Docket Report from Jul. 20, 2020, in Case No. 0:18-cv-03227 (37 pages). |
Plaintiff Protégé Biomedical, LLC's Objections to the Magistrate Judge's May 26, 2020 Order on Its Motion to for leave to Amend its First Amended Complaint, dated Jun. 9, 2020, in Case No. 0:18-cv-03227 (16 pages). |
Final Consent Judgment and Permanent Injunction, dated Aug. 13, 2020, in Case No. 0:18-cv-03227 (4 pages). |
A Docket Report from Sep. 9, 2020, in Case No. 0:18-cv-03227 (38 pages). |
Plaintiff Protégé Biomedical, LLC's Motion for Preliminary Injunction, dated Dec. 12, 2018, in Case No. 0:18-cv-03227 (4 pages). |
Plaintiff Protégé Biomedical, LLC's Memo in Support of Preliminary Injunction, dated Dec. 12, 2018, in Case No. 0:18-cv-03227 (34 pages). |
Defendant Z-Medica, LLC's Partial Opposition to P's Motion for Leave to Amend, dated Mar. 20, 2020, in Case No. 0:18-cv-03227 (36 pages). |
Declaration of Charles N. Nauen and Exhibits in Support of Defendant Z-Medica, LLC's Partial Opposition to P's Motion for Leave to Amend, dated Mar. 20, 2020, in Case No. 0:18-cv-03227 (15 pages). |
Redacted Exhibit C of Declaration of Charles N. Nauen in Support of Defendant Z-Medica, LLC's Partial Opposition to P's Motion for Leave to Amend, dated Mar. 20, 2020, in Case No. 0:18-cv-03227 (8 pages). |
Stipulation to Amend Schedule, dated Mar. 27, 2020, in Case No. 0:18-cv-03227 (4 pages). |
Amended Joint Claim Construction Statement, dated Mar. 27, 2020, in Case No. 0:18-cv-03227 (5 pages). |
Joint Claim Construction Letter, dated Mar. 27, 2020, in Case No. 0:18-cv-03227 (2 pages). |
Order to Amend Schedule, dated Mar. 30, 2020, in Case No. 0:18-cv-03227 (2 pages). |
Plaintiff Protégé Biomedical, LLC's Objections to the Magistrate Judge's Mar. 17, 2020 Order on Its Motion to Compel the Production of Privileged Documents, dated Mar. 31, 2020, in Case No. 0:18-cv-03227 (16 pages). |
Declaration of Laura Conley and Exhibits in Support of Plaintiff Protégé Biomedical, LLC's Objections to the Magistrate Judge's Mar. 17, 2020 Order on Its Motion to Compel the Production of Privileged Documents, dated Mar. 31, 2020, in Case No. 0:18-cv-03227 (19 pages). |
Declaration of Philip O'Beirne and Exhibits in Support of Defendant Z-Medica, LLC's Submission for Attorneys' Fees, dated Mar. 31, 2020, in Case No. 0:18-cv-03227 (10 pages). |
Plaintiff Protégé Biomedical, LLC's Reply Memorandum in Support of Leave to Amend, dated Apr. 2, 2020, in Case No. 0:18-cv-03227 (35 pages). |
Order Regarding Payment of D's Attorney Fees, dated Apr. 6, 2020, in Case No. 0:18-cv-03227 (2 pages). |
Defendant Z-Medica, LLC's Sur-Reply in Support Partial Opposition to P's Motion for Leave to Amend, dated Apr. 6, 2020, in Case No. 0:18-cv-03227 (18 pages). |
Declaration of Charles N. Nauen and Exhibits in Support of Defendant Z-Medica, LLC's Sur-Reply, dated Apr. 6, 2020, in Case No. 0:18-cv-03227 (1 page). |
Declaration of Jack Y. Perry in Support of Plaintiff Protégé Biomedical, LLC's in Support of P's Motion for Leave to Amend First Amended Complaint, dated Apr. 13, 2020, in Case No. 0:18-cv-03227 (1 page). |
Declaration of Philip O'Beirne in Support of Defendant Z-Medica, LLC's Opposition to P's Motion for Leave to Amend, dated Apr. 14, 2020, in Case No. 0:18-cv-03227 (3 pages). |
Redacted Response by Defendant Z-Medica, LLC's in Response to P's Motions of Mar. 17, 2020, dated Apr. 14, 2020, in Case No. 0:18-cv-03227 (17 pages). |
Supplemental Declaration of Jack Y. Perry in Support of Plaintiff Protégé Biomedical, LLC's in Support of P's Motion for Leave to Amend First Amended Complaint, dated Apr. 15, 2020, in Case No. 0:18-cv-03227 (3 pages). |
Plaintiff Protégé Biomedical, LLC's Request for Oral Hearing, dated Apr. 17, 2020, in Case No. 0:18-cv-03227 (2 pages). |
A Docket Report from May 27, 2020, in Case No. 0:18-cv-03227 (33 pages). |
Number | Date | Country | |
---|---|---|---|
20180271898 A1 | Sep 2018 | US |
Number | Date | Country | |
---|---|---|---|
61385388 | Sep 2010 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15641999 | Jul 2017 | US |
Child | 15995672 | US | |
Parent | 14995592 | Jan 2016 | US |
Child | 15641999 | US | |
Parent | 14479214 | Sep 2014 | US |
Child | 14995592 | US | |
Parent | 13240795 | Sep 2011 | US |
Child | 14479214 | US |